- Nestle (NSRGY) and Fresenius are the last two potential buyers of Danone's $5.5B Medical Nutrition business still standing.
- Nestle is already a big player in the market while Fresenius says the Danone business will complement its Kabi division that makes tube and IV feeding equipment and generic infusion drugs.
- Danone will likely use the proceeds to expand its baby food and dairy businesses.
- Unsurprisingly, the parties decline to comment at this time.
From other sites
at MarketWatch.com (Jan 15, 2015)
at Nasdaq.com (Jan 9, 2015)
at Nasdaq.com (Jan 2, 2015)
at Nasdaq.com (Dec 29, 2014)
at Nasdaq.com (Dec 24, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs